Your cart is empty.
Männedorf, Switzerland, March 27, 2013 - The Tecan Group (SIX Swiss Exchange: TECN) today announced the publication of its 2012 Annual Report in the Investor Relations section of the company's website at www.tecan.com. An iPad App for the Tecan Financial Reports is available from the App Store. Tecan already published its 2012 financial results in a press release and at the Press Briefing on Annual Results and Analysts' Conference held on March 7, 2013. Today also saw the publication and dispatch of the notice of the Annual General Meeting of the Tecan Group AG. The Annual General Meeting will take place on April 17, 2013. The notice is also published on the company's website.
Further increase in distribution to shareholders
On the basis of a strong balance sheet and a sustainable good business outlook, Tecan intends to increase its profit distribution to shareholders again. The Board of Directors will therefore propose a 20% increase in the dividend from CHF 1.25 to CHF 1.50 per share to the shareholders at the Company's Annual General Meeting on April 17, 2013. The dividend will be paid out in part from the available capital contribution reserve, and this portion of CHF 1.00 is therefore not subject to withholding tax.
Election to the Board of Directors
As previously announced, the Board of Directors will propose the election of Dr. Christa Kreuzberg as a new member of the Board at the Annual General Meeting. Dr. Kreuzburg is an experienced manager from the pharma industry, and has held a range of management positions at Bayer AG. Most recently, she was a member of the Executive Committee of Bayer HealthCare and Head of Bayer Schering Pharma Europe/Canada.
The Board will also propose the reelection of current members Rolf A. Classon, Heinrich Fischer, Dr. Oliver S. Fetzer, Gérard Vaillant, Erik Walldén and Dr. Karen Huebscher for a further one-year term. Dominique F. Baly will not seek reelection at this year's Annual General Meeting.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2012, Tecan generated sales of CHF 391 million (USD 416 million; EUR 323 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89